---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021367"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:44:10.440346+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q1 net loss narrows to $28.4M; cash $299M into 2027; Biogen milestone $8M, Merck deal up to $740M

## Summary
- Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.
- Cash $299.2M as of Mar 31; expected runway into 2027.
- Earned $8M from Biogen; Merck KGaA collaboration with $16M upfront and up to $740M milestones.
- Phase 1 trials for cemsidomide (MM/NHL) and CFT1946 (solid tumors) progressing; data expected 2H 2024.
- Appointed Dan Powers as SVP clinical development.

## SEC filing metadata
- accession: 0001628280-24-021367
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/0001628280-24-021367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/cccc-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021367
- JSON: https://secwatch.observer/filing/0001628280-24-021367.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021367.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.0 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $3.0 million
  - Result: reported results
  source text: Total revenue for the first quarter of 2024 was $3.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/0001628280-24-021367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.